doi:10.1182/blood-2017-07-795302engSalar, AntonioDomingo-Domenech, EvaPanizo, CarlosNicolás, ConcepciónBargay, JoanMuntañola, AnaCanales, MiguelBello, José LuisSancho, Juan ManuelTomás, José FranciscoRodríguez, María JoséPeñalver, JavierGrande, CarlosSánchez-Blanco, José JavierPalomera, LuisArranz, ReyesConde, EulogioGarcía, MarGarcía, Juan FernandoCaballero, DoloresMontalbán, CarlosLong-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphomaART-2017-101907To the editor: Extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue (MALT) present in most cases as localized disease and can be successfully treated with local therapies or antibiotics.1¿¿-4 Moreover, patients with multicentric or extensive disease or relapsed disease may require systemic treatment with chemotherapy and/or rituximab.5¿¿-8 Also, considering the relative frequency of late relapses9 and that extragastric MALT lymphomas have an increased relapse risk, 10 systemic treatment has also been used in the first-line setting. Several chemotherapy agents, anti-CD20 monoclonal antibodies, immunomodulatory agents, and their combinations have been demonstrated to be effective specifically in MALT lymphomas.11¿¿-14 Herewith, we report the long-term results of the MALT 2008-01 phase 2 trial15 using a response-adapted protocol with the combination of rituximab and bendamustine (RB) as first-line treatment of MALT lymphomas after a median follow-up of 7 years. This trial was registered at www.clinicaltrials.gov as #NCT01015248 and in EudraCT as #2008-007725-39....2017http://zaguan.unizar.es/record/16540510.1182/blood-2017-07-795302http://zaguan.unizar.es/record/165405oai:zaguan.unizar.es:165405Blood 130, 15 (2017), 1772-1774All rights reservedhttp://www.europeana.eu/rights/rr-f/info:eu-repo/semantics/closedAccess